Baxter Theranova: More Middle Molecules, Less Albumin Loss
Baxter’s new dialyzer mimics the function of natural kidneys more closely, removing more middle molecules with no replacement fluid needed—and minimal loss of vital albumin. The new expanded hemodialysis (HDx) therapy has been tested in the UK, where it reduced beta-2 microglobulin levels by more than 11%
Read the full article » | Posted 12-14-2017
Related Articles
- Dr. Ben Reynolds and the Virtual Reality Kidney Dialysis Training Project Posted 06-17-2026
- HollyTM Implantable Continuous Dialysis System Could be Ready for Human Trials Soon Posted 04-14-2026
- Xeltis is Trialing its Polymer-based Vascular Access Posted 03-12-2026
- New Bluetooth-enabled CAPD System Enhanced Patient Satisfaction Posted 03-12-2026

